OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$13.45
0.05 (0.37%)
▲
5d:
+0.07%
30d:
+0.22%
90d:
+120.85%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Distribution
None View Scanner →
Strength: 6.0/10
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: OGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: OGN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.38
Based on 2.6% avg growth
INTRINSIC VALUE TODAY
$6.44
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $13.45, which is considered extended relative to its 30-day fair value range of $13.37 to $13.44. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.7) compared to its historical average (2.5). At these levels, the market is pricing in 14.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.37. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.37. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.37 -
$13.44
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
40.5%
Protect Your Profits
OGN is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 16.4% above Wall St target ($11.25)
- NEUTRAL: Trading at premium valuation - market expects 14.3% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$13.37 -
$13.44
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.37
Resistance Level
$13.49
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.67
Wall Street Target
$11.25
(-16.4%)
Revenue Growth (YoY)
-3.5%
Earnings Growth (YoY)
66.7%
Profit Margin
4.0%
Valuation Premium vs History
+14.3% premium
PE vs Historical
3.7 vs 2.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.3%
(market-implied from PE analysis)
1-Year Target
$15.37
(+14%)
2-Year Target
$17.57
(+31%)
3-Year Target
$20.08
(+49%)
3-Yr Target (if PE normalizes)
(PE: 4→3)
PE COMPRESSION
$13.67
(+2%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 1.1%)
$82.45
(+513%)
Base:
(SPY PE: 3.7, Growth: 1.1%)
$13.91
(+3%)
Bear:
(PE: 2.5, Growth: 1.1%)
$9.46
(-30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 14.41 | Current EPS (TTM): $0.93
Bull Case
$29.48
(+119%)
Analyst growth 100.0%, PE expands to 15.9
Base Case
$26.80
(+99%)
Market implied 100.0%, PE stable at 14.4
Bear Case
$9.11
(-32%)
Severe decline -20.0%, PE contracts to 12.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 11:04 PM ET
Data refreshes hourly during market hours. Next update: 12:04 AM
Data refreshes hourly during market hours. Next update: 12:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 52 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 56 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 64 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 63 BUY |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
